Cyclosporine A improves survival in lower-risk hypoplastic myelodysplastic syndromes: a single-center retrospective study from China
Year: 2025
Type: article
Language: en
Topic: Acute Myeloid Leukemia Research
Authors and affiliations:
raw_author_name: Yumei Liu
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Tianjin Institute of Hematology, Tianjin, People's Republic of China
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
raw_author_name: Liyan Yang
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Yansong Wei
raw_affiliation_strings: Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
raw_author_name: Wei Zhang
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Huijuan Jiang
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Lijuan Li
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Limin Xing
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Zonghong Shao
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Rong Fu
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China
raw_author_name: Huaquan Wang
raw_affiliation_strings: Tianjin Institute of Hematology
Tianjin Key Laboratory of Bone Marrow Failure and Malignant Hemopoietic Clone Control
Tianjin Medical University General Hospital
Department of Hematology, Tianjin Medical University General Hospital, Tianjin, People's Republic of China
Tianjin Institute of Hematology, Tianjin, People's Republic of China